All AbMole products are for research use only, cannot be used for human consumption.
In vitro: The estimated EC50 for total 8 concentration in plasma is 3.8 μM, which corresponds well with the IC50 value obtained in the human whole blood assay of 1.9 μM.
In vivo: PF-06282999 is moderately bound to plasma proteins across preclinical species and humans. The blood/plasma ratios for PF-06282999 are 1.1, 1.1, 0.91, 1.2, and 0.94 in mice, rats, dogs, monkeys, and humans, respectively, suggesting that PF-06282999 is equally distributed into plasma and red blood cells. The in vivo pharmacokinetics of PF-06282999 are examined in greater detail in mice, rats, dogs, and monkeys, wherein it is demonstrated to have low CLp in mice (10.1 mL/min/kg), dogs (3.39 mL/min/kg), monkeys (10.3 mL/min/kg) and moderate CLp in rats (41.8 mL/min/kg). The terminal plasma elimination half-lives (t1/2) range from 0.75 to 3.3 h in the four species. Approximately 26-32% of the iv dose of PF-06282999 is excreted in the unchanged form in rat, dog, and monkey urine, wherein it is also shown that it is well distributed with steady state distribution volumes (Vdss) ranging from 0.5-2.1 L/kg in mice, rats, dogs, and monkeys. Following oral administration, PF-06282999 is rapidly (Tmax=0.78-1.70 h) and well absorbed in mice, rats, dogs, and monkeys with oral bioavailability values of 100%, 86%, 75%, and 76%, respectively.
| Cell Experiment | |
|---|---|
| Cell lines | HepaRG KO Cell Lines |
| Preparation method | Following the pre-incubation period, cells were treated with 200 μl/well of the prepared 1x-concentration treatment medium with control DMSO (0.1%), PF 06282999 (1-600 μM) or rifampin (0.03-30 μM). |
| Concentrations | 1-600 μM |
| Incubation time | 48 h |
| Animal Experiment | |
|---|---|
| Animal models | |
| Formulation | |
| Dosages | |
| Administration | |
| Molecular Weight | 325.77 |
| Formula | C13H12ClN3O3S |
| CAS Number | 1435467-37-0 |
| Form | Solid |
| Solubility (25°C) | 32 mg/mL in DMSO |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Products |
|---|
| D-Allulose
D-Allulose (D-Psicose) is an ultralow-energy monosaccharide sugar. It is a C-3 epimer of D-fructose, and is present in small quantities in agricultural products and commercially-prepared carbohydrate complexes. |
| N,N-Dimethyltrifluoromethanesulfonamide
N,N-Dimethyltrifluoromethanesulfonamide (DMTMSA) is a trifluoromethanesulfonamide solvent. |
| Lucicebtide
Lucicebtide is a peptide antagonist of the transcription factor C/EBPβ, a key activator of the transcriptional program in immunosuppressive macrophages. Lucicebtide shows highly potent inhibition against C/EBPB-ATF5 association with IC50 of 24.6 nM in a competitive ELISA assay. |
| Eloralintide
Eloralintide (LY 3841136) is an AMYR agonist. |
| Gadoteric acid
Gadoteric acid is a macrocyclic, paramagnetic, gadolinium-based contrast agent that can be used for magnetic resonance imaging (MRI) of the brain, spine, and related tissues. Gadoteric acid is able to detect and visualize areas of blood-brain barrier disruption and abnormal vascular distribution. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
